BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25773928)

  • 21. Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.
    Cai H; Li X; Li J; Ao L; Yan H; Tong M; Guan Q; Li M; Guo Z
    Oncotarget; 2015 Dec; 6(42):44593-608. PubMed ID: 26527319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HOXD13 methylation status is a prognostic indicator in breast cancer.
    Zhong Z; Shan M; Wang J; Liu T; Xia B; Niu M; Ren Y; Pang D
    Int J Clin Exp Pathol; 2015; 8(9):10716-24. PubMed ID: 26617782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of GP88 (progranulin) expression in breast tumor biopsies improves the risk predictive value of the Nottingham Prognostic Index.
    Serrero G; Hawkins DM; Bejarano PA; Ioffe O; Tkaczuk KR; Elliott RE; Head JF; Phillips J; Godwin AK; Weaver J; Hicks D; Yue B
    Diagn Pathol; 2016 Aug; 11(1):71. PubMed ID: 27501955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer.
    Niikura N; Iwamoto T; Masuda S; Kumaki N; Xiaoyan T; Shirane M; Mori K; Tsuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
    Cancer Sci; 2012 Aug; 103(8):1508-12. PubMed ID: 22537114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
    Sun M; Wu D; Zhou K; Li H; Gong X; Wei Q; Du M; Lei P; Zha J; Zhu H; Gu X; Huang D
    Breast Cancer Res Treat; 2019 May; 175(1):59-75. PubMed ID: 30715658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.
    Kensler KH; Poole EM; Heng YJ; Collins LC; Glass B; Beck AH; Hazra A; Rosner BA; Eliassen AH; Hankinson SE; Winer EP; Brown M; Tamimi RM
    J Natl Cancer Inst; 2019 Jul; 111(7):700-708. PubMed ID: 30445651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
    Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
    Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
    Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Body mass index is associated with gene methylation in estrogen receptor-positive breast tumors.
    Hair BY; Troester MA; Edmiston SN; Parrish EA; Robinson WR; Wu MC; Olshan AF; Swift-Scanlan T; Conway K
    Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):580-6. PubMed ID: 25583948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
    Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
    PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes linked to expression of gene subsets for protein hormones and their cognate receptors from LCM-procured breast carcinoma cells.
    Daniels MW; Brock GN; Wittliff JL
    Breast Cancer Res Treat; 2017 Jan; 161(2):245-258. PubMed ID: 27858316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of key genes relevant to the prognosis of ER-positive and ER-negative breast cancer based on a prognostic prediction system.
    Xiao B; Hang J; Lei T; He Y; Kuang Z; Wang L; Chen L; He J; Zhang W; Liao Y; Sun Z; Li L
    Mol Biol Rep; 2019 Apr; 46(2):2111-2119. PubMed ID: 30888555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.
    Murphy NC; Biankin AV; Millar EK; McNeil CM; O'Toole SA; Segara D; Crea P; Olayioye MA; Lee CS; Fox SB; Morey AL; Christie M; Musgrove EA; Daly RJ; Lindeman GJ; Henshall SM; Visvader JE; Sutherland RL
    Int J Cancer; 2010 Mar; 126(6):1445-53. PubMed ID: 19676041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
    Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
    BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes.
    Győrffy B; Bottai G; Fleischer T; Munkácsy G; Budczies J; Paladini L; Børresen-Dale AL; Kristensen VN; Santarpia L
    Int J Cancer; 2016 Jan; 138(1):87-97. PubMed ID: 26174627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.
    Sicking I; Rommens K; Battista MJ; Böhm D; Gebhard S; Lebrecht A; Cotarelo C; Hoffmann G; Hengstler JG; Schmidt M
    BMC Cancer; 2014 Dec; 14():952. PubMed ID: 25511800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.